Aldeyra Therapeutics
ALDX
89 hedge funds and large institutions have $249M invested in Aldeyra Therapeutics in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 13 reducing their positions, and 8 closing their positions.
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
247% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $571K
158% more capital invested
Capital invested by funds: $96.4M → $249M (+$152M)
138% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 13
35% more funds holding
Funds holding: 66 → 89 (+23)
25.21% more ownership
Funds ownership: 60.33% → 85.54% (+25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$8.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.73M |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$2.92M |
| 4 |
6CM
683 Capital Management
New York
|
+$2.84M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.91M |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$786K |
| 3 |
JP Morgan Chase
New York
|
-$455K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$312K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$141K |
ALDX Hedge Fund Activity: Q3 2018 in Review
89 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2018, worth a combined $249M — up 158% from $96.4M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ALDX positions and 8 closed out — a net gain of 23 holders — while 31 added to existing stakes and 13 trimmed.
The largest buyer was Citigroup, adding an estimated $8.27M. The largest seller was Adage Capital Partners, cutting an estimated $2.91M.
- 89 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2018, up from 66 in Q2 2018.
- Funds reported $249M of Aldeyra Therapeutics stock for Q3 2018, up 158% quarter-over-quarter.
- 31 funds opened new Aldeyra Therapeutics positions in Q3 2018 and 8 closed out, a net change of +23 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2018 was Citigroup, an estimated $8.27M added.
- The largest Aldeyra Therapeutics seller in Q3 2018 was Adage Capital Partners, an estimated $2.91M sold.
Based on aggregated 13F filings for Q3 2018.